Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65

Deep News

07/21

Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.

Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its "Buy" rating on the stock, with a target price set at HK$65.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1144611319"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144611319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144611319?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144611319","market":"nz","top_or_hot":-1,"title":"Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65","media":"Deep News","content":"<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-21 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1144611319","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144611319","pubTimestamp":1784646085,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK1583":"高瓴概念","EWH":"香港ETF-iShares MSCI","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","06618":"京东健康","BK1571":"互联网医疗","BK1615":"港股-互联网","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1247":"药品零售","BK1142":"互联网与直销零售","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1591":"就地过年概念","LU0051755006.USD":"摩根大通中国A (dist)"},"translate_title":"高盛确认京东健康买入评级，目标价65港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":1,"EWH":1,"06618":1},"content_text":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}